Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Relevant studies demonstrated that the expression of PD-L1 in glioma correlates with WHO grading and could be considered as a tumor biomarker.
|
31661771 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also tested the expression of PD-L1 in six glioma cell lines.
|
31152305 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, the delivery efficiency of PD-L1-targeted LNPs was robustly enhanced in the context of radiation therapy (RT) owing to the RT-induced up-regulation of PD-L1 on glioma-infiltrating TAMCs.
|
31712430 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of IL6 signaling in orthotopic murine glioma models was associated with reduced myeloid PD-L1 expression, diminished tumor growth, and increased survival.
|
30824583 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Glioma treatment using targeted chemotherapy is still far from satisfactory due to not only the limited accumulation but also the multiple survival mechanisms of glioma cells, including up-regulation of both autophagy and programmed cell death ligand 1 (PD-L1) expression.
|
31610656 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that combining CD48 blockade with PD-L1 may be a promising approach to glioma immunotherapy for specific subpopulations of patients.
|
31213836 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We modified an immune-competent, genetically-driven mouse glioma model (forced PDGF expression + PTEN loss) where a portion of the tumor burden is irradiated (PDGF) and another un-irradiated luciferase expressing tumor (PDGF+Luciferase) is used as a readout of the abscopal effect following systemic anti-PD-L1 immunotherapy.
|
31793634 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Utilizing the immune checkpoint inhibitor antiprogrammed death ligand 1 (PD-L1) (αPD-L1) to prepare αPD-L1 Chloringlobulin, we have demonstrated a combination of Ce6-based red-light fluorescence image-guided surgery, stereotactic PDT, and PD-L1 blockade therapy of mice bearing orthotopic glioma.
|
31397999 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our data indicate that in glioma cells, PD-L1 is induced to prevent autophagic cytoskeleton collapse via Akt binding/activation, facilitating glioma cell invasion upon starvation stress.
|
31850228 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RT could up-regulate the PD-L1 expression through the pathways downstream of EGFR in glioma.
|
29396299 |
2018 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The IFN-γ level was positively correlated with PD-L1 expression in murine glioma.
|
30333036 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also summarize the relationships between PD-L1 and immune cell infiltration in glioma.
|
30687086 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that PD-L1 may expand and maintain immunosuppressive Tregs, which are associated with decreased survival in glioma patients.
|
29900065 |
2018 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We tested the predictive value of a "31-gene signature" and PD-L1 expression status in a dataset of patients with lower grade glioma.
|
29784449 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, TIM-3 is a promising target for immunotherapeutic strategies, providing an alternative treatment when glioma gains resistance to antibodies of PD-1/PD-L1.
|
28919992 |
2017 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies have reported that the PD-1/PD-L1 pathway plays a key role in glioma progression and in the efficacy of immunotherapies.
|
28388955 |
2017 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PD-L1 may represent a promising biomarker that predicts disease progression in patients with glioma or GBM.
|
28652622 |
2017 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glioma cell may escape from immune recognition and injury with the help of PD-L1, which is a significant pathogenic mechanism of glioma.
|
28490949 |
2017 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quantitative real-time PCR analysis showed that miR-34a level was lower, but PD-L1 expression level was higher in glioma tissue specimens compared with normal brain tissues and their expression levels were negatively correlated.
|
28721584 |
2017 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Because gliomas can express PD-L1 causing a defective host anti-tumoral immunity, we investigated whether FKBP51s was expressed in glioma and played a role in PD-L1 regulation in this tumour.
|
28978117 |
2017 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, further research should be conducted to assess the combination of targeted VEGF therapy and anti-PD-L1 immunotherapy for the treatment of glioma.
|
28591697 |
2017 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) across glioma grades is undocumented, and their interactions with commonly expressed genetic and epigenetic alterations are undefined but nonetheless highly relevant to combinatorial treatments.
|
27370400 |
2016 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.
|
26266810 |
2015 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ifnb-/- neurons lacked PD-L1 and were defective in inducing glioma cell death; this effect was reversed on PD-L1 gene transfection.
|
23986257 |
2013 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment of normal monocytes with glioma-conditioned media could significantly increase B7-H1 expression.
|
23613317 |
2013 |